Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex)
A 65-year-old female presented with visual disturbance in her right eye lasting for over 2 months. Following investigations, she was diagnosed with MacTel type 1 in the right eye. Visual symptoms were refractory to initial treatment with intravitreal bevacizumab and thereafter intravtireal triamicin...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Case Reports in Ophthalmological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2014/231913 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555958149054464 |
|---|---|
| author | Mohamed Loutfi Thomas Papathomas Ahmed Kamal |
| author_facet | Mohamed Loutfi Thomas Papathomas Ahmed Kamal |
| author_sort | Mohamed Loutfi |
| collection | DOAJ |
| description | A 65-year-old female presented with visual disturbance in her right eye lasting for over 2 months. Following investigations, she was diagnosed with MacTel type 1 in the right eye. Visual symptoms were refractory to initial treatment with intravitreal bevacizumab and thereafter intravtireal triamicinolone. The patient was then treated with Ozurdex, following which central macular thickness (CMT) decreased (from 397 μm to 286 μm) and visual acuity deteriorated (from logMAR 0.48 to 0.59). At 14 weeks posttreatment with Ozurdex, a recurrence of cystoid macular oedema (CMO) was observed. Following a second Ozurdex, visual acuity improved (from logMAR 0.7 to 0.64) and CMT decreased (from 349 μm to 279 μm). An additional recurrence of CMO was observed at eighteen weeks following the second Ozurdex. Following a third Ozurdex injection visual acuity deteriorated (from logMAR 0.74 to 0.78) and CMT decreased (from 332 μm to 279 μm). Conclusion. Treatment of macular oedema secondary to MacTel with Ozurdex demonstrated promising anatomical outcomes. However, visual outcomes continued to gradually deteriorate. |
| format | Article |
| id | doaj-art-d2eeaacc053747249eabe285f5e7852e |
| institution | Kabale University |
| issn | 2090-6722 2090-6730 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Ophthalmological Medicine |
| spelling | doaj-art-d2eeaacc053747249eabe285f5e7852e2025-02-03T05:46:45ZengWileyCase Reports in Ophthalmological Medicine2090-67222090-67302014-01-01201410.1155/2014/231913231913Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex)Mohamed Loutfi0Thomas Papathomas1Ahmed Kamal2University of Liverpool Medical School, Liverpool L69 3BX, UKEye Unit, Royal Cornwall Hospital, Treliske, Truro TR1 3LJ, UKOphthalmology Department, Aintree University Hospital, Longmoor Lane, Liverpool L9 7AL, UKA 65-year-old female presented with visual disturbance in her right eye lasting for over 2 months. Following investigations, she was diagnosed with MacTel type 1 in the right eye. Visual symptoms were refractory to initial treatment with intravitreal bevacizumab and thereafter intravtireal triamicinolone. The patient was then treated with Ozurdex, following which central macular thickness (CMT) decreased (from 397 μm to 286 μm) and visual acuity deteriorated (from logMAR 0.48 to 0.59). At 14 weeks posttreatment with Ozurdex, a recurrence of cystoid macular oedema (CMO) was observed. Following a second Ozurdex, visual acuity improved (from logMAR 0.7 to 0.64) and CMT decreased (from 349 μm to 279 μm). An additional recurrence of CMO was observed at eighteen weeks following the second Ozurdex. Following a third Ozurdex injection visual acuity deteriorated (from logMAR 0.74 to 0.78) and CMT decreased (from 332 μm to 279 μm). Conclusion. Treatment of macular oedema secondary to MacTel with Ozurdex demonstrated promising anatomical outcomes. However, visual outcomes continued to gradually deteriorate.http://dx.doi.org/10.1155/2014/231913 |
| spellingShingle | Mohamed Loutfi Thomas Papathomas Ahmed Kamal Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex) Case Reports in Ophthalmological Medicine |
| title | Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex) |
| title_full | Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex) |
| title_fullStr | Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex) |
| title_full_unstemmed | Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex) |
| title_short | Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex) |
| title_sort | macular oedema related to idiopathic macular telangiectasia type 1 treated with dexamethasone intravitreal implant ozurdex |
| url | http://dx.doi.org/10.1155/2014/231913 |
| work_keys_str_mv | AT mohamedloutfi macularoedemarelatedtoidiopathicmaculartelangiectasiatype1treatedwithdexamethasoneintravitrealimplantozurdex AT thomaspapathomas macularoedemarelatedtoidiopathicmaculartelangiectasiatype1treatedwithdexamethasoneintravitrealimplantozurdex AT ahmedkamal macularoedemarelatedtoidiopathicmaculartelangiectasiatype1treatedwithdexamethasoneintravitrealimplantozurdex |